Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative

JAMA

Volumn 311, Issue 16, 2014, Pages 1632-1640

  Fonarow, Gregg C ^a   Zhao, Xin ^b   Smith, Eric E ^c   Saver, Jeffrey L ^a   Reeves, Mathew J ^d   Bhatt, Deepak L ^e   Xian, Ying ^b   Hernandez, Adrian F ^b   Peterson, Eric D ^b   Schwamm, Lee H ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL DECISION MAKING; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; FEMALE; HOSPITAL CARE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TIME TO TREATMENT; TOTAL QUALITY MANAGEMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HOSPITAL MORTALITY; HOSPITALS; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PATIENT DISCHARGE; QUALITY IMPROVEMENT; REGISTRIES; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84898811265     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.3203     Document Type: Article

References (29)

1. Jauch EC, Saver JL, Adams HP Jr, et al American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947.
2. Tissue plasminogen activator for acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587.
3. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379(9834):2364-2372.
4. Lees KR, Bluhmki E, von Kummer R, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695-1703.
5. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55(11):1649-1655.
6. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40(6):2079-2084.
7. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480-2488.
8. Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7):750-758.
9. Marler JR, Winters Jones P, Emr M. The National Institute of Neurological Disorders and Stroke: Proceedings of National Symposium on Rapid Identification and Treatment of Acute Stroke. Bethesda, MD: National Institute of Neurological Disorders and Stroke; 1997.
10. Alberts MJ, Hademenos G, Latchaw RE, et al Brain Attack Coalition. Recommendations for the establishment of primary stroke centers. JAMA. 2000;283(23):3102-3109. (Pubitemid 30399721)
11. Summers D, Leonard A, Wentworth D, et al American Heart Association Council on Cardiovascular Nursing and the Stroke Council. Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient: a scientific statement from the American Heart Association [published correction appears in Stroke. 2010;41(9):e563]. Stroke. 2009;40(8):2911-2944.
12. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283(9):1145-1150. (Pubitemid 30126602)
13. Fonarow GC, Smith EE, Saver JL, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative. Stroke. 2011;42(10):2983-2989.
14. Berwick DM. The science of improvement. JAMA. 2008;299(10):1182-1184. (Pubitemid 351398433)
15. Shojania KG, Grimshaw JM. Evidence-based quality improvement: the state of the science. Health Aff (Millwood). 2005;24(1):138-150. (Pubitemid 40169783)
16. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009;119(1):107-115.
17. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies, 2: assessing potential for confounding. BMJ. 2005;330(7497):960-962. (Pubitemid 40592320)
18. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006;25(12):2084-2106. (Pubitemid 43950281)
19. Wahlgren N, Ahmed N, Dávalos A, et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-282. (Pubitemid 46138121)
20. Tveiten A, Mygland A, Ljøstad U, Thomassen L. Intravenous thrombolysis for ischaemic stroke: short delays and high community-based treatment rates after organisational changes in a previously inexperienced centre. Emerg Med J. 2009;26(5):324-326.
21. Lindsberg PJ, Häppölä O, Kallela M, Valanne L, Kuisma M, Kaste M. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. Neurology. 2006;67(2):334-336. (Pubitemid 44305430)
22. Mehdiratta M, Woolfenden AR, Chapman KM, et al. Reduction in IV t-PA door to needle times using an Acute Stroke Triage Pathway. Can J Neurol Sci. 2006;33(2):214-216. (Pubitemid 43845177)
23. Gomez CR, Malkoff MD, Sauer CM, Tulyapronchote R, Burch CM, Banet GA. Code stroke: an attempt to shorten inhospital therapeutic delays. Stroke. 1994;25(10):1920-1923. (Pubitemid 24291273)
24. SITS International. Reduction of in-hospital delays in stroke thrombolysis: SITS-WATCH. http://clinicaltrials.gov/show/NCT01811901. Accessed December 3, 2013.
25. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79(4):306-313.
26. Krumholz HM, Bradley EH, Nallamothu BK, et al. A campaign to improve the timeliness of primary percutaneous coronary intervention: door-to-balloon: an alliance for quality. JACC Cardiovasc Interv. 2008;1(1):97-104. (Pubitemid 351459373)
27. Bradley EH, Curry LA, Webster TR, et al. Achieving rapid door-to-balloon times: how top hospitals improve complex clinical systems. Circulation. 2006;113(8):1079-1085.
28. Menees DS, Peterson ED, Wang Y, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med. 2013;369(10):901-909.
29. Xian Y, Fonarow GC, Reeves MJ, et al. Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. Am Heart J. 2012;163(3):392-398, e1.